CHAMP (Prostate Cancer)

Purpose of this Study

We are doing this study to learn if a combination of chemotherapies and immunotherapies (carboplatin, cabazitaxel, nivolumab and ipilimumab) slows cancer growth in patients with metastatic neuroendocrine or aggressive variant prostate cancer.

We also want to learn about the types of side effects that patients have while they are taking these study drugs together.

Who Can Participate?

Eligibility

Adults with neuroendocrine or aggressive variant prostate cancer who:<ul
<li>Have not already had an immunotherapy drug to treat their cancer</li>
<li>Have not already had cabazitaxel</li></ul>

Age Range

18-110

Sex/Genders

Male (cisgender)
Looking for Healthy Participants
No

What is Involved?

If you join this study you will:<ul>
<li>Get study drugs given to you through a needle in a vein in your arm every 3 weeks</li>
<li>Have imaging tests</li>
<li>Have blood and urine tests</li>
<li>Complete questionnaires</li></ul>

Locations

Duke University Hospital
Duke Raleigh Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

A Phase II, Single Arm Study of Chemoimmunotherapy for the Treatment of Men with Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)

Principal Investigator

Andrew
Armstrong

Protocol Number

PRO00106278

NCT ID

NCT04709276

Phase

II

Enrollment Status

Open to Enrollment